Table 2 Summary of cell line cross-resistance to drug treatment

A2780

1.83

3.37

6.34

10.8

(0.94–3.14)

(2.84–3.76)

(5.76–7.04)

(5.76–20.0)

1

1

1

1

A2780CR1

7,49

3.43

41.5

37.3

(5.39–8.72)

(3.09–3.93)

(32.8–48.0)

(31.7–43.7)

4.09 ↑ *

1.01

6.54 ↑ **

3.45

A2780CR2

6.03

3.86

6.84

8.59

(5.12–7.10)

(3.13–4.48)

(6.07–8.02)

(8.09–9.11)

3.29 ↑ *

1.15

1.08

0.79

A2780DR1

1.79

283

367

37.3

(1.64–1.96)

(123–601)

(253–496)

(33.5–41.0)

0.98

84 ↑ **

58 ↑ **

3.45

A2780DR2

2.32

569

461

30,9

(0.86–3.06)

(407–983)

(353–596)

(22.1–38.6)

1.27

169 ↑ **

73 ↑ **

2.86

A2780TR1

0.84

4.13

46.4

644

(0.36–1.40)

(3.56–4.65)

(34.6–68.6)

(350–851)

0.46

1.22

7.3 ↑ *

59.6 ↑ **

A2780TR2

4.24

40.5

192

523

(2.91–4.95)

(24.7–56.6)

(59.4–252)

(409–616)

2.31

12 ↑ **

30 ↑ *

48.5 ↑ **

A2780PR1

3.41

491

419

61.4

(1.86–4.57)

(457–534)

(384–464)

(49.9–70.3)

1.86

146 ↑ **

66 ↑ **

5.68 ↑ *

A2780PR2

15.5

4052

22,673

1398

(9.31–22.4)

(3872–4452)

(29,757–14,104)

(880–1913)

8.46 ↑ **

1202 ↑ **

3476 ↑ **

129 ↑ **